 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Mylan Inc. (MYL) is a pharmaceutical company. The firm develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.
It operates in two segments, Generics and Specialty.
The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies.
The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan.
Shares have formed a bullish "cup and handle" following the company's quarterly report on October 30th. Earnings came in on the high end of the raised guidance range that Mylan offered on Oct. 3, at $1.16 a share. That was up 41% from the year-earlier quarter and 2 cents better than analysts' consensus. Sales jumped 18% to $2.08 billion, $27 million above estimates. We expect higher share prices for this stock.
52-Weeks Trading Range: $41.26 - $57.52
Entry Point: $55.75
Stop Loss: $53.10
Target Price: $61.60
We are taking profits on MYL at $57.32 after its 30 days expired without reaching our target.
